Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- GR1501 high dose · Oncology
GR1501 high dose is a small molecule that targets the PD-1 receptor. - GR1501 low dose
GR1501 is a low-dose drug that targets a specific molecular pathway. - GR1801
GR1801 is an investigational therapeutic in phase 3 development by Genrix Biopharmaceutical, but its specific mechanism of action is not publicly disclosed. - GR1802 injection · Oncology
GR1802 injection is a monoclonal antibody targeting the PD-1 receptor. - GR1803 · Oncology
GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. - GR2001
GR2001 is an investigational biopharmaceutical in phase 3 development by Genrix, but its specific mechanism of action is not publicly disclosed.
Phase 2 pipeline
- IL-17A antibody · Immunology
IL-17A antibody targets the IL-17A receptor
Phase 1 pipeline
- Anti-CD38 Monoclonal Antibody · Oncology
Monoclonal antibody targeting CD38
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: